A melanoma cell line (MZ7), derived from a patient who received dacarbazine therapy, exhibited a high level of resistance to temozolomide (TMZ) without expressing O(6)-methylguanine-DNA methyltransferase (MGMT), which was related to impaired expression of MSH2 and MSH6 (87). Here, MSH2 is linked to melanoma.